Business Context and Reporting Period
Company: Zenas BioPharma, Inc. (ZBIO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Zenas is a clinical-stage biopharmaceutical company focused on immunology and inflammation (I&I) therapies. The company operates as a single reportable segment. Key product candidates include obexelimab (lead asset for IgG4-RD, SLE, and MS), orelabrutinib (BTK inhibitor for MS), and early-stage assets ZB021 and ZB022.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $1.0 million | $10.0 million |
| Net Loss | $(192.4) million | $(85.8) million |
| Net Loss Per Share (Basic & Diluted) | $(3.24) | $(2.05) |
| Operating Expenses | $186.0 million | $102.5 million |
| Research & Development (R&D) | $123.4 million | $77.9 million |
| General & Administrative (G&A) | $32.7 million | $24.6 million |
| Acquired In-Process R&D | $30.0 million | $0 |
| Cash, Cash Equivalents & Investments | $673.9 million | $360.5 million (Dec 31, 2025) |
| Accumulated Deficit | $(957.6) million | $(765.1) million (Dec 31, 2025) |
Debt & Liquidity:
- Senior Secured Term Loan: $75.0 million principal outstanding (Tranche A funded March 2026). Carrying value: $74.1 million.
- Convertible Senior Notes: $230.0 million principal outstanding (issued March/April 2026). Carrying value: $223.0 million.
- Royalty Obligation: $91.7 million liability related to Royalty Pharma agreement.
- Working Capital: Current assets of $653.8 million vs. current liabilities of $65.8 million.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased $9.0 million year-over-year (YoY) due to the recognition of a $10.0 million upfront payment from the Zai License Agreement in the prior period, compared to only $1.0 million in milestone revenue from the Tenacia Agreement in the current period.
- Expense Surge: Total operating expenses increased $83.5 million YoY.
- R&D Increase: Driven by $21.3 million in costs for the new orelabrutinib program and $7.9 million for obexelimab clinical trials.
- Acquired IPR&D: A one-time $30.0 million charge was recorded for milestones achieved under Xencor ($10.0 million) and InnoCare ($20.0 million) agreements.
- Financing Activity: Significant capital raised in the first half of 2026, including $223.1 million from convertible notes, $108.1 million from equity offerings, and $73.5 million from the term loan, resulting in a net cash increase of $85.9 million.
- Interest Expense: New debt instruments (Term Loan, Convertible Notes, Royalty Obligation) resulted in $16.9 million of additional interest expense compared to the prior period.
Guidance, Outlook, and Risks
Outlook & Liquidity:
- Management expects existing cash and investments ($673.9 million) to fund operations into 2029.
- Assuming receipt of potential $75 million milestones from Royalty Pharma and Pharmakon upon FDA approval of obexelimab for IgG4-RD, liquidity is projected to extend through Q2 2029.
- Revenue from product sales is not expected until 2027 at the earliest.
Key Milestones & Events:
- Obexelimab: FDA accepted the Biologics License Application (BLA) for IgG4-RD in August 2026 with a PDUFA date of May 27, 2027. Phase 2 SLE trial (SunStone) topline data expected Q4 2026.
- Orelabrutinib: Phase 3 trials initiated for PPMS and naSPMS.
- Subsequent Events: In August 2026, BMS achieved a regulatory milestone triggering a $10.0 million payment to Zenas. Zenas also achieved a near-term milestone with InnoCare, triggering a $25.0 million payment and issuance of 2 million shares.
Risks & Contingencies:
- Debt Covenants: The Term Loan requires a minimum liquidity of $50.0 million and, if drawn above $200 million, a minimum trailing twelve-month revenue covenant.
- Regulatory & Clinical: Risks associated with clinical trial outcomes, FDA approval timelines, and the ability to commercialize products.
- Geopolitical: Exposure to tariffs and supply chain disruptions, particularly regarding imports from China for drug substance and components.
- Management Transition: CFO Jennifer Fox is transitioning to a Strategic Advisor role effective September 30, 2026, with Joseph Farmer appointed as interim Principal Financial Officer.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $673.9 million cash balance against the projected burn rate, specifically the impact of the new debt service obligations (Term Loan and Convertible Notes).
- Debt Terms: Review the specific triggers for the $225 million potential milestone payments from Royalty Pharma and the $250 million Term Loan tranches (Tranche B through E) to understand future dilution or cash flow requirements.
- Obexelimab Approval: Monitor the FDA review process for the IgG4-RD BLA (PDUFA May 2027) as this is the primary catalyst for revenue generation and debt milestone triggers.
- Subsequent Milestone Payments: Confirm the timing and accounting treatment of the $10 million BMS milestone and the $25 million InnoCare milestone announced in August 2026.
- Management Continuity: Assess the impact of the CFO transition on financial reporting and strategic execution.